Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Editas Medicine Shares Jump After Stifel Turns Bullish

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr Therapeutics 2Q Loss/Shr 98c >CRSP

Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst

Pfizer Bets on Caribou's Gene-Edited Cancer Treatment

Gene Editing Is Working. Wall Street Is Taking Notice.

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months

CRISPR Therapeutics Stock Joins Rank Of Stocks With RS Ratings Over 90

CRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89

Crispr Therapeutics Stock Climbs 13% on Narrower 1Q Loss

Crispr Therapeutics 1Q Loss/Shr 67c >CRSP

IBD 50 Stocks To Watch: Vertex Pharmaceuticals In Buy Zone As Firm Gets On A Roll

CRISPR Shares Up 16% After Positive Cantor Fitzgerald Report

CRISPR Therapeutics: Announces Transition of Chief Fincl Officer

Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy

Crispr Therapeutics Stock Gains on Hope for Sickle-Cell Gene Therapy

Thematic ETFs Look Tempting. Just Say No.

Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success

Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead